S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Allakos Stock Forecast, Price & News

-4.64 (-4.00 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $111.38
50-Day Range
MA: $132.23
52-Week Range
Now: $111.38
Volume186,683 shs
Average Volume313,118 shs
Market Capitalization$5.85 billion
P/E RatioN/A
Dividend YieldN/A
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Allakos logo


Allakos Appoints Natalie Holles to its Board of Directors
December 22, 2020 |  finance.yahoo.com
Benzinga's Top Upgrades, Downgrades For December 21, 2020
December 21, 2020 |  finance.yahoo.com
Is ALLK A Good Stock To Buy Now? - Yahoo Finance
December 12, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALLK
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$10.19 per share


Net Income$-85,370,000.00


Market Cap$5.85 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.66 out of 5 stars

Medical Sector

274th out of 1,968 stocks

Pharmaceutical Preparations Industry

128th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
-4.64 (-4.00 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos
or view top-rated stocks.

What stocks does MarketBeat like better than Allakos?

Wall Street analysts have given Allakos a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allakos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Allakos?

Allakos saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,510,000 shares, a decrease of 15.8% from the December 31st total of 4,170,000 shares. Based on an average trading volume of 325,400 shares, the days-to-cover ratio is currently 10.8 days. Currently, 11.3% of the company's stock are sold short.
View Allakos' Short Interest

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Allakos

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its earnings results on Sunday, February, 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.02.
View Allakos' earnings history

How has Allakos' stock price been impacted by Coronavirus?

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALLK stock has increased by 91.0% and is now trading at $111.38.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALLK?

5 brokers have issued 12-month target prices for Allakos' shares. Their forecasts range from $145.00 to $218.00. On average, they expect Allakos' share price to reach $181.50 in the next year. This suggests a possible upside of 63.0% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Dr. Robert Alexander, CEO & Director (Age 51, Pay $1.01M)
  • Dr. Adam L. Tomasi, Pres, COO & Sec. (Age 51, Pay $781.27k)
  • Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 58, Pay $573.67k)
  • Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 62, Pay $627.59k)
  • Dr. Ruby Casareno Ph.D., Sr. VP of Technical Operations
  • Dr. Simon Greenwood, Chief Bus. Officer
  • Dr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.
  • Mr. Tim Varacek, Chief Commercial Officer
  • Mr. Alan Chang, Director of Medical Affairs & Data Analytics

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.72%), Baker BROS. Advisors LP (1.36%), Alliancebernstein L.P. (0.95%), Northern Trust Corp (0.60%), Norges Bank (0.54%) and Charles Schwab Investment Management Inc. (0.40%). Company insiders that own Allakos stock include Adam Tomasi, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker and Venture Fund (Ohi Rivervest II.
View institutional ownership trends for Allakos

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Candriam Luxembourg S.C.A., Alliancebernstein L.P., SG Americas Securities LLC, Aviva PLC, Jane Street Group LLC, ClariVest Asset Management LLC, and State of Wisconsin Investment Board. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, and Paul Edward Walker.
View insider buying and selling activity for Allakos
or view top insider-selling stocks.

Which major investors are buying Allakos stock?

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Voloridge Investment Management LLC, Charles Schwab Investment Management Inc., Northern Trust Corp, Baker BROS. Advisors LP, Federated Hermes Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for Allakos
or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $111.38.

How much money does Allakos make?

Allakos has a market capitalization of $5.85 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 114 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

Where are Allakos' headquarters?

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.